{"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"15"}],"units":"Participants"}],"groups":[{"description":"In Phase 1, participants received oral INCB001158 75 milligrams (mg) twice daily (BID) in 28-day cycles starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment continued until disease progression, unacceptable toxicity, or discontinuation from study treatment for any other reason.","id":"BG000","title":"Phase 1: INCB001158 75 mg BID + Daratumumab"},{"description":"In Phase 1, participants received oral INCB001158 100 mg BID in 28-day cycles starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment continued until disease progression, unacceptable toxicity, or discontinuation from study treatment for any other reason.","id":"BG001","title":"Phase 1: INCB001158 100 mg BID + Daratumumab"},{"description":"In Phase 1, participants received oral INCB001158 100 mg BID in 28-day cycles starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment continued until disease progression, unacceptable toxicity, or discontinuation from study treatment for any other reason.","id":"BG002","title":"Phase 2: INCB001158 100 mg BID + Daratumumab"},{"description":"In Part 1 of Phase 2, participants received daratumumb 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2 (28-day cycles), once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. At the time of confirmed disease progression, participants crossed over to Part 2 of Phase 2 to receive oral INCB001158 100 mg BID starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment in Phase 2 continued for as long as participants were receiving clinical benefit and did not met any criteria for study withdrawal.","id":"BG003","title":"Phase 2: Daratumumab Monotherapy; Cross Over to INCB001158 + Daratumumab"},{"description":"In Part 1 of Phase 2, participants received oral INCB001158 100 mg BID in 28-day cycles starting at Cycle 1. At the time of confirmed disease progression, participants crossed over to Part 2 of Part 2 to receive oral INCB001158 100 mg BID starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment in Phase 2 continued for as long as participants were receiving clinical benefit and did not met any criteria for study withdrawal.","id":"BG004","title":"Phase 2: INCB001158 Monotherapy; Cross Over to INCB001158 + Daratumumab"},{"description":"Total of all reporting groups","id":"BG005","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.70","value":"65.0"},{"groupId":"BG001","spread":"9.83","value":"68.0"},{"groupId":"BG002","spread":"12.73","value":"67.0"},{"comment":"To protect participant privacy, a mean age and standard deviation are not reported for a single participant.","groupId":"BG003","spread":"NA","value":"NA"},{"groupId":"BG004","spread":"19.09","value":"71.5"},{"groupId":"BG005","spread":"10.59","value":"67.1"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"comment":"To protect participant privacy, sex is not reported for a single participant.","groupId":"BG003","value":"NA"},{"groupId":"BG004","value":"0"},{"comment":"Total not calculated because data are not available (NA) in one or more arms.","groupId":"BG005","value":"NA"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"comment":"To protect participant privacy, sex is not reported for a single participant.","groupId":"BG003","value":"NA"},{"groupId":"BG004","value":"2"},{"comment":"Total not calculated because data are not available (NA) in one or more arms.","groupId":"BG005","value":"NA"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"comment":"To protect participant privacy, ethnicity is not reported for a single participant.","groupId":"BG003","value":"NA"},{"groupId":"BG004","value":"1"},{"comment":"Total not calculated because data are not available (NA) in one or more arms.","groupId":"BG005","value":"NA"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"2"},{"comment":"To protect participant privacy, ethnicity is not reported for a single participant.","groupId":"BG003","value":"NA"},{"groupId":"BG004","value":"1"},{"comment":"Total not calculated because data are not available (NA) in one or more arms.","groupId":"BG005","value":"NA"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"comment":"To protect participant privacy, ethnicity is not reported for a single participant.","groupId":"BG003","value":"NA"},{"groupId":"BG004","value":"0"},{"comment":"Total not calculated because data are not available (NA) in one or more arms.","groupId":"BG005","value":"NA"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"comment":"To protect participant privacy, race is not reported for a single participant.","groupId":"BG003","value":"NA"},{"groupId":"BG004","value":"0"},{"comment":"Total not calculated because data are not available (NA) in one or more arms.","groupId":"BG005","value":"NA"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"comment":"To protect participant privacy, race is not reported for a single participant.","groupId":"BG003","value":"NA"},{"groupId":"BG004","value":"0"},{"comment":"Total not calculated because data are not available (NA) in one or more arms.","groupId":"BG005","value":"NA"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"comment":"To protect participant privacy, race is not reported for a single participant.","groupId":"BG003","value":"NA"},{"groupId":"BG004","value":"0"},{"comment":"Total not calculated because data are not available (NA) in one or more arms.","groupId":"BG005","value":"NA"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"comment":"To protect participant privacy, race is not reported for a single participant.","groupId":"BG003","value":"NA"},{"groupId":"BG004","value":"0"},{"comment":"Total not calculated because data are not available (NA) in one or more arms.","groupId":"BG005","value":"NA"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"2"},{"comment":"To protect participant privacy, race is not reported for a single participant.","groupId":"BG003","value":"NA"},{"groupId":"BG004","value":"2"},{"comment":"Total not calculated because data are not available (NA) in one or more arms.","groupId":"BG005","value":"NA"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"comment":"To protect participant privacy, race is not reported for a single participant.","groupId":"BG003","value":"NA"},{"groupId":"BG004","value":"0"},{"comment":"Total not calculated because data are not available (NA) in one or more arms.","groupId":"BG005","value":"NA"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"comment":"To protect participant privacy, race is not reported for a single participant.","groupId":"BG003","value":"NA"},{"groupId":"BG004","value":"0"},{"comment":"Total not calculated because data are not available (NA) in one or more arms.","groupId":"BG005","value":"NA"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}]}